Announces phase 1 study with Foxy-5 is completed
WntResearch today announces that the last patient, in their on-going clinical phase 1 study with Foxy-5, has completed treatment at the last dose level (dose level 8) according to the protocol. As the Foxy-5 phase 1 study thereby is closed, data will be analysed and a summary report will be developed and presented during Q4. Some patients will continue their treatment for as long as their treating physician finds it appropriate. Nils Brünner, CEO says, ”We are very pleased that we now have closed the Foxy-5 phase 1 study and look forward to explore the data and present it in a summary